52 Week Range
As of on the Euronext Paris ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Novacyt Receives Notice Of Exercise Of Warrants For New Shares
Novacyt Expects Lower FY EBITDA, Develops Coronavirus Test
Novacyt Signs 3-Year Deal With VGS Group For Distribution Of Molecular Diagnostic Products In France
Novacyt SA is a France-based company that develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The Company develops a secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The Company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of over 10 distributors.
13 avenue Morane Saulnier
James Christopher Wakefield
Independent Non-Executive Chairman
Graham D. Mullis
Chief Executive Officer, Executive Director, Member of the Executive Team
Anthony William Dyer
Chief Financial Officer, Executive Director, Company Secretary, Member of the Executive Team
Member of the Executive Team, Group Human Resource Manager
Member of the Executive Team, Corporate & Investor Relations Manager
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Biotechnology company Novacyt said on Friday it would launch a certified test for the coronavirus next week, sending its London-listed shares to a record high.
* NOVACYT S.A. - UPDATE ON CE MARK APPROVED CORONAVIRUS TEST
Shares in biotech company Novacyt , which is launching a coronavirus test, surged on Monday to extend previous big gains made this year on investor hopes it could win regulatory approval for its coronavirus test product.
Biotechnology company Novacyt has applied for emergency approval from the U.S. Food & Drug Administration (FDA) as it races to roll out a product that tests for the coronavirus, the company said on Friday.
Biotechnology company Novacyt <ALNOV.PA> <NCYT.L> said on Friday it has applied for emergency approval from the U.S. Food & Drug Administration (FDA) for a test product for the coronavirus that has killed almost 640 people.
Biotechnology company Novacyt said on Friday it has applied for emergency approval from the U.S. Food & Drug Administration (FDA) for a test product for the coronavirus that has killed almost 640 people.
Healthcare company Novacyt <ALNOV.PA> said on Friday it had launched a new molecular test for the coronavirus currently afflicting China and other parts of the world.
Healthcare company Novacyt said on Friday it had launched a new molecular test for the coronavirus currently afflicting China and other parts of the world.
Healthcare company Novacyt said on Friday that it had launched a new molecular test for coronavirus, which is currently afflicting China and other parts of the world.
* FY NET LOSS EUR 5.4 MILLION VERSUS EUR 5.7 MILLION YEAR AGO
* SIGNS ASSAY DEVELOPMENT CONTRACT FOR DIAGNOSIS OF RESPIRATORY INFECTIONS WITH GENEPOC
* ANNOUNCES FULL REDEMPTION AND SETTLEMENT OF 40 PENDING CONVERTIBLE BONDS ( "OCA") UNDER YORKVILLE FACILITY AGREEMENT, WITH IMMEDIATE EFFECT
* SHARES ADMITTED TO TRADING ON AIM, MARKET OPERATED BY LONDON STOCK EXCHANGE, FROM 8 AM GMT ON NOV 1
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.